FRIDAY, Oct. 4, 2024 — Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to severely active ulcerative colitis than placebo, according to a phase…Original Article
Anti-TL1A Monoclonal Antibody, Tulisokibart, Aids Ulcerative Colitis
FRIDAY, Oct. 4, 2024 — Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to severely active ulcerative colitis than placebo, according to a phase…
